Literature DB >> 22116093

Soluble vascular adhesion protein-1 correlates with cardiovascular risk factors and early atherosclerotic manifestations.

Kristiina Aalto1, Mikael Maksimow, Markus Juonala, Jorma Viikari, Antti Jula, Mika Kähönen, Sirpa Jalkanen, Olli T Raitakari, Marko Salmi.   

Abstract

OBJECTIVE: Vascular adhesion protein-1 is an endothelial enzyme that regulates leukocyte traffic and contributes to vascular damage in animal models. The relations of soluble vascular adhesion protein-1 (sVAP-1) with cardiovascular risk factors and markers of subclinical atherosclerosis at a population level have not been studied. METHODS AND
RESULTS: We developed a new high-throughput method and measured sVAP-1 activities in serum of 2183 persons (The Cardiovascular Risk in Young Finns Study). In women, sVAP-1 activity correlated indirectly with body mass index (r=-0.15, P<0.0001), triglycerides (r=-0.13, P<0.0001), C-reactive protein (r=-0.23; P<0.0001), and brachial artery flow-mediated vasodilatation (r=-0.076, P=0.0089) and directly with carotid plaques (r=0.066, P=0.023). None of these correlations was significant in men. In women, all these univariate correlations remained significant after adjustment for body mass index, and direct correlations with LDL-cholesterol (r=0.094, P=0.0014) and carotid intima-media thickness (r=0.075, P=0.010) became evident. In men, sVAP-1 activity associated directly with glucose (r=0.074, P=0.020), intima-media thickness (r=0.072, P=0.025), metabolic syndrome (P=0.016), and type 1 (P=0.0002) and type 2 (P<0.0001) diabetes. In multivariable analyses, sVAP-1 activity was an independent determinant of carotid intima-media thickness (P=0.0072) and plaques [odds ratio 1.71 (95% confidence interval 1.07-2.72, P=0.025] in women, but not in men.
CONCLUSIONS: sVAP-1 activity correlates directly with intima-media thickness and carotid plaques in general population and may play a role in the pathophysiology of preclinical atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22116093     DOI: 10.1161/ATVBAHA.111.238030

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  22 in total

Review 1.  Importance of receptor-targeted systems in the battle against atherosclerosis.

Authors:  Elisabet Rosas; Igor Sobenin; Alexander Orekhov; Elazer R Edelman; Mercedes Balcells
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 2.  Ectoenzymes in leukocyte migration and their therapeutic potential.

Authors:  Marko Salmi; Sirpa Jalkanen
Journal:  Semin Immunopathol       Date:  2014-03-18       Impact factor: 9.623

3.  Circulating vascular adhesion protein-1(VAP-1): a possible biomarker for liver fibrosis associated with chronic hepatitis B and C.

Authors:  Zehra Öksüz; Enver Üçbilek; Mehmet Sami Serin; Serkan Yaraş; Gülhan Orekici Temel; Orhan Sezgin
Journal:  Braz J Microbiol       Date:  2020-09-21       Impact factor: 2.476

4.  Feasibility of (68)Ga-labeled Siglec-9 peptide for the imaging of acute lung inflammation: a pilot study in a porcine model of acute respiratory distress syndrome.

Authors:  Jaime Retamal; Jens Sörensen; Mark Lubberink; Fernando Suarez-Sipmann; João Batista Borges; Ricardo Feinstein; Sirpa Jalkanen; Gunnar Antoni; Göran Hedenstierna; Anne Roivainen; Anders Larsson; Irina Velikyan
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-01-28

5.  Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis.

Authors:  Chris J Weston; Emma L Shepherd; Lee C Claridge; Pia Rantakari; Stuart M Curbishley; Jeremy W Tomlinson; Stefan G Hubscher; Gary M Reynolds; Kristiina Aalto; Quentin M Anstee; Sirpa Jalkanen; Marko Salmi; David J Smith; Christopher P Day; David H Adams
Journal:  J Clin Invest       Date:  2014-12-22       Impact factor: 14.808

6.  Leukocyte trafficking-associated vascular adhesion protein 1 is expressed and functionally active in atherosclerotic plaques.

Authors:  Johanna M U Silvola; Helena Virtanen; Riikka Siitonen; Sanna Hellberg; Heidi Liljenbäck; Olli Metsälä; Mia Ståhle; Tiina Saanijoki; Meeri Käkelä; Harri Hakovirta; Seppo Ylä-Herttuala; Pekka Saukko; Matti Jauhiainen; Tibor Z Veres; Sirpa Jalkanen; Juhani Knuuti; Antti Saraste; Anne Roivainen
Journal:  Sci Rep       Date:  2016-10-12       Impact factor: 4.379

7.  Association between metabolically healthy central obesity in women and levels of soluble receptor for advanced glycation end products, soluble vascular adhesion protein-1, and the activity of semicarbazide-sensitive amine oxidase.

Authors:  Ivana Koborová; Radana Gurecká; Melinda Csongová; Katarína Volkovová; Éva Szökő; Tamás Tábi; Katarína Šebeková
Journal:  Croat Med J       Date:  2017-04-14       Impact factor: 1.351

8.  Comparison of 68Ga-DOTA-Siglec-9 and 18F-Fluorodeoxyribose-Siglec-9: Inflammation Imaging and Radiation Dosimetry.

Authors:  Helena Virtanen; Johanna M U Silvola; Anu Autio; Xiang-Guo Li; Heidi Liljenbäck; Sanna Hellberg; Riikka Siitonen; Mia Ståhle; Meeri Käkelä; Anu J Airaksinen; Kerttuli Helariutta; Tuula Tolvanen; Tibor Z Veres; Antti Saraste; Juhani Knuuti; Sirpa Jalkanen; Anne Roivainen
Journal:  Contrast Media Mol Imaging       Date:  2017-12-31       Impact factor: 3.161

9.  Serum Vascular Adhesion Protein-1 Predicts End-Stage Renal Disease in Patients with Type 2 Diabetes.

Authors:  Hung-Yuan Li; Hung-An Lin; Feng-Jung Nien; Vin-Cent Wu; Yi-Der Jiang; Tien-Jyun Chang; Hsien-Li Kao; Mao-Shin Lin; Jung-Nan Wei; Cheng-Hsin Lin; Shyang-Rong Shih; Chi-Sheng Hung; Lee-Ming Chuang
Journal:  PLoS One       Date:  2016-02-04       Impact factor: 3.240

10.  Evidence that endogenous formaldehyde produces immunogenic and atherogenic adduct epitopes.

Authors:  Jun Nakamura; Takasumi Shimomoto; Leonard B Collins; Darcy W Holley; Zhenfa Zhang; Jenna M Barbee; Vyom Sharma; Xu Tian; Tomohiro Kondo; Koji Uchida; Xianwen Yi; Diana O Perkins; Monte S Willis; Avram Gold; Scott J Bultman
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.